Fig. 4From: Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 monthsHistogram comparing times Zero and m1318 distribution of HIT6 scores for patients who remained on treatment beyond June 2021Back to article page